Search results
Results From The WOW.Com Content Network
August 1, 2024 at 2:31 PM. Moderna ( MRNA) shares slid more than 20% Thursday after the company slashed its sales guidance for 2024, largely because of a lack of new COVID-19 vaccine orders from ...
Moderna's mRNA platform now features a long list of candidates, and the biotech still has enough cash on hand -- $12.2 billion as of the end of the first quarter -- to fund its programs despite a ...
The company's stock was trading slightly up on the news early Monday before falling after market open. Moderna is up almost 20% in the last month after the company received approval from the FDA ...
Shares of Moderna soared around 14% on Thursday on the news that a personalized cancer vaccine, produced in partnership with Merck, reduced the risk of late-stage melanoma by 49%.
Moderna Current Valuation and Performance. Moderna stock sits at $146.36 per share as of Feb. 17, 2022. Depending on which analyst you believe, you should expect either a loss of 42% or gains of ...
On Thursday, Moderna Inc (NASDAQ:MRNA) stock plunged as the company lowered its 2024 sales guidance due to weaker demand for its COVID-19 vaccines. Moderna now projects 2024 net sales of between ...
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The ...
mRNA specialist Moderna (MRNA) is among the leading players in the race to be first to market with a COVID-19 vaccine and the market has been kind in return. Overall, the stock is up 254% year-to ...